Clinical Trials Logo

Stage III Multiple Myeloma clinical trials

View clinical trials related to Stage III Multiple Myeloma.

Filter by:

NCT ID: NCT00522392 Terminated - Clinical trials for Stage III Multiple Myeloma

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Start date: September 2007
Phase: Phase 3
Study type: Interventional

This randomized phase III trial compares bortezomib, dexamethasone, and lenalidomide with bortezomib and dexamethasone to see how well they work in treating patients with multiple myeloma previously treated with dexamethasone. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. It is not yet known whether giving bortezomib and dexamethasone is more effective with or without lenalidomide in treating multiple myeloma.

NCT ID: NCT00514137 Completed - Clinical trials for Refractory Multiple Myeloma

Sunitinib in Treating Patients With Relapsed Multiple Myeloma

Start date: September 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sunitinib works in treating patients with relapsed multiple myeloma. Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer

NCT ID: NCT00489203 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Start date: April 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Beclomethasone dipropionate may be effective in preventing acute graft-versus-host disease in patients undergoing a stem cell transplant for hematologic cancer. PURPOSE: This randomized phase II trial is studying how well beclomethasone dipropionate works in preventing acute graft-versus-host disease in patients undergoing a donor stem cell transplant for hematologic cancer.

NCT ID: NCT00437034 Terminated - Clinical trials for Stage III Multiple Myeloma

Aflibercept for Relapsed Multiple Myeloma

Start date: January 2007
Phase: Phase 2
Study type: Interventional

This phase II trial is studying the side effects and how well aflibercept works in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment. Aflibercept may be able to carry cancer-killing substances directly to multiple myeloma cells. It may also stop the growth of multiple myeloma by blocking blood flow to the cancer.

NCT ID: NCT00410605 Active, not recruiting - Clinical trials for Refractory Multiple Myeloma

Bevacizumab, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Stage II or Stage III Multiple Myeloma

Start date: November 2006
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving bevacizumab together with lenalidomide and dexamethasone works in treating patients with relapsed or refractory stage II or stage III multiple myeloma. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab and lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Dexamethasone may stimulate the immune system in different ways and stop cancer cells from growing. Giving bevacizumab together with lenalidomide and dexamethasone may kill more cancer cells.

NCT ID: NCT00408681 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease After Donor Stem Cell Transplant

Start date: June 2006
Phase: N/A
Study type: Interventional

RATIONALE: Lithium carbonate may be an effective treatment for intestinal graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This clinical trial is studying lithium carbonate in treating patients with acute intestinal graft-versus-host-disease after donor stem cell transplant.

NCT ID: NCT00398515 Completed - Clinical trials for Refractory Multiple Myeloma

Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma

Start date: March 2007
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of temsirolimus when given together with lenalidomide in treating patients with previously treated multiple myeloma. Lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Temsirolimus may also stop the growth of cancer cells by blocking some of the enzymes needed for their growth. Giving lenalidomide together with temsirolimus may kill more cancer cells.

NCT ID: NCT00310024 Completed - Clinical trials for Refractory Multiple Myeloma

Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Start date: November 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating patients with relapsed or refractory multiple myeloma. Vorinostat and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more cancer cells

NCT ID: NCT00303797 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

Start date: December 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of sorafenib and bortezomib in treating patients with advanced cancer. Sorafenib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of cancer cells by blocking blood flow to the cancer

NCT ID: NCT00243035 Terminated - Clinical trials for Refractory Multiple Myeloma

Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

Start date: August 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of tipifarnib when given together with bortezomib and to see how well they work in treating patients with relapsed multiple myeloma. Tipifarnib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving tipifarnib together with bortezomib may kill more cancer cells.